Management of basal cell carcinoma with pulmonary metastasis.
Dermatology
Malignant disease and immunosuppression
Plastic and reconstructive surgery
Skin
Skin cancer
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
04 Jan 2023
04 Jan 2023
Historique:
entrez:
4
1
2023
pubmed:
5
1
2023
medline:
7
1
2023
Statut:
epublish
Résumé
A man in his 50s presented with an ulcerative lesion within the left axillary fold that had progressively worsened over 18 months. Biopsy revealed an ulcerative basal cell carcinoma (BCC), which was surgically managed. CT chest scans done 7 months later assessed post-treatment of radiotherapy. This revealed pulmonary lesions, which were biopsy-proven metastatic BCC. Sonidegib, a hedgehog signalling inhibitor, was used for first-line treatment. Due to progressive disease, sonidegib was ceased. Cemiplimab, a checkpoint inhibitor, was used as second-line treatment based on a phase II trial demonstrating efficacy in the setting of metastatic BCC. CT reports were initially consistent with response but after 6 months of cemiplimab treatment, repeat CT chest scans revealed a decrease in size of the previously cited pulmonary lesions.This is a rare case of BCC metastases which has limited treatment options. This case provides insight of the patient experience on such treatment.
Identifiants
pubmed: 36599494
pii: 16/1/e251700
doi: 10.1136/bcr-2022-251700
pii:
doi:
Substances chimiques
sonidegib
0RLU3VTK5M
Hedgehog Proteins
0
Pyridines
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.